COMMUNIQUÉS West-GlobeNewswire

Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
20/03/2024
Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall following his retirement Announces changes to its Board of Directors, appoints new Board Chair CHASKA, Minn [...]
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
20/03/2024
GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial [...]
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
20/03/2024
23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also induces Fc receptor-mediated killing of ULBP6-expressing cancer cells [...]
Aurora Spine Corporation Celebrates Second Anniversary of Initial Implantation of the World’s First Bone Density Matched DEXA-C Cervical Interbody Fusion Device
20/03/2024
CARLSBAD, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a manufacturer of innovative spinal implants announced today that it has [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
20/03/2024
PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today [...]
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
20/03/2024
Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024 LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of [...]
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
20/03/2024
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of [...]
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
20/03/2024
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatment Actively adding sites and enrolling pivotal Phase 3 [...]
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
20/03/2024
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its [...]
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023
20/03/2024
Efforts now aligned toward the completion of its First Quarter Fiscal 2024 Report on Form 10-Q CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a [...]
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
20/03/2024
TUSTIN, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (Nasdaq:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received a notice (the “ [...]
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
20/03/2024
Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide individualized support throughout [...]
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
20/03/2024
SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
20/03/2024
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye [...]
MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
20/03/2024
Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating wounds MARIETTA, Ga., March 20, 2024 (GLOBE [...]
Evaxion organise la journée de la recherche et développement et dévoile le vaste potentiel de sa plateforme AI-Immunology™
20/03/2024
La plateforme AI-Immunology™ brevetée ouvre la voie d'une nouvelle ère dans le monde de la découverte, de la conception et du développement de vaccins grâce à des technologies avancées d'IA et d'apprentissage [...]
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
20/03/2024
Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024 Aiming for first oncology launch in 2026 and ten indication [...]
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
20/03/2024
Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief [...]
Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology
20/03/2024
Press Release Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology First publication of the data from the Mont Blanc Phase 3 trial in a peer-reviewed [...]

Pages